275 related articles for article (PubMed ID: 33590450)
1. Lonafarnib: First Approval.
Dhillon S
Drugs; 2021 Feb; 81(2):283-289. PubMed ID: 33590450
[TBL] [Abstract][Full Text] [Related]
2. Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells.
Arnold R; Vehns E; Randl H; Djabali K
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299092
[TBL] [Abstract][Full Text] [Related]
3. FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies.
Suzuki M; Jeng LJB; Chefo S; Wang Y; Price D; Li X; Wang J; Li RJ; Ma L; Yang Y; Zhang X; Zheng N; Zhang K; Joseph DB; Shroff H; Doan J; Pacanowski M; Smpokou P; Donohue K; Joffe HV
Genet Med; 2023 Feb; 25(2):100335. PubMed ID: 36507973
[TBL] [Abstract][Full Text] [Related]
4. Genetic and pharmacological modulation of lamin A farnesylation determines its function and turnover.
Foo MXR; Ong PF; Yap ZX; Maric M; Bong CJS; Dröge P; Burke B; Dreesen O
Aging Cell; 2024 May; 23(5):e14105. PubMed ID: 38504487
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome.
Gordon LB; Kleinman ME; Miller DT; Neuberg DS; Giobbie-Hurder A; Gerhard-Herman M; Smoot LB; Gordon CM; Cleveland R; Snyder BD; Fligor B; Bishop WR; Statkevich P; Regen A; Sonis A; Riley S; Ploski C; Correia A; Quinn N; Ullrich NJ; Nazarian A; Liang MG; Huh SY; Schwartzman A; Kieran MW
Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16666-71. PubMed ID: 23012407
[TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts.
Bikkul MU; Clements CS; Godwin LS; Goldberg MW; Kill IR; Bridger JM
Biogerontology; 2018 Dec; 19(6):579-602. PubMed ID: 29907918
[TBL] [Abstract][Full Text] [Related]
7. Transient introduction of human telomerase mRNA improves hallmarks of progeria cells.
Li Y; Zhou G; Bruno IG; Zhang N; Sho S; Tedone E; Lai TP; Cooke JP; Shay JW
Aging Cell; 2019 Aug; 18(4):e12979. PubMed ID: 31152494
[TBL] [Abstract][Full Text] [Related]
8. Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria.
Yang SH; Chang SY; Andres DA; Spielmann HP; Young SG; Fong LG
J Lipid Res; 2010 Feb; 51(2):400-5. PubMed ID: 19965595
[TBL] [Abstract][Full Text] [Related]
9. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition.
Glynn MW; Glover TW
Hum Mol Genet; 2005 Oct; 14(20):2959-69. PubMed ID: 16126733
[TBL] [Abstract][Full Text] [Related]
10. Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome.
Gordon LB; Kleinman ME; Massaro J; D'Agostino RB; Shappell H; Gerhard-Herman M; Smoot LB; Gordon CM; Cleveland RH; Nazarian A; Snyder BD; Ullrich NJ; Silvera VM; Liang MG; Quinn N; Miller DT; Huh SY; Dowton AA; Littlefield K; Greer MM; Kieran MW
Circulation; 2016 Jul; 134(2):114-25. PubMed ID: 27400896
[TBL] [Abstract][Full Text] [Related]
11. Lonafarnib for cancer and progeria.
Wong NS; Morse MA
Expert Opin Investig Drugs; 2012 Jul; 21(7):1043-55. PubMed ID: 22620979
[TBL] [Abstract][Full Text] [Related]
12. Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis.
Moorthy NS; Sousa SF; Ramos MJ; Fernandes PA
Curr Med Chem; 2013; 20(38):4888-923. PubMed ID: 24059235
[TBL] [Abstract][Full Text] [Related]
13. Targeting protein prenylation in progeria.
Young SG; Yang SH; Davies BS; Jung HJ; Fong LG
Sci Transl Med; 2013 Feb; 5(171):171ps3. PubMed ID: 23390246
[TBL] [Abstract][Full Text] [Related]
14. Plasma Progerin in Patients With Hutchinson-Gilford Progeria Syndrome: Immunoassay Development and Clinical Evaluation.
Gordon LB; Norris W; Hamren S; Goodson R; LeClair J; Massaro J; Lyass A; D'Agostino RB; Tuminelli K; Kieran MW; Kleinman ME
Circulation; 2023 Jun; 147(23):1734-1744. PubMed ID: 36919608
[TBL] [Abstract][Full Text] [Related]
15. Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome.
Gordon LB; Shappell H; Massaro J; D'Agostino RB; Brazier J; Campbell SE; Kleinman ME; Kieran MW
JAMA; 2018 Apr; 319(16):1687-1695. PubMed ID: 29710166
[TBL] [Abstract][Full Text] [Related]
16. Farnesyltransferase inhibition in HGPS.
Misteli T
Cell; 2021 Jan; 184(2):293. PubMed ID: 33482093
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome.
Capell BC; Erdos MR; Madigan JP; Fiordalisi JJ; Varga R; Conneely KN; Gordon LB; Der CJ; Cox AD; Collins FS
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12879-84. PubMed ID: 16129833
[TBL] [Abstract][Full Text] [Related]
18. Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation.
Yang SH; Qiao X; Fong LG; Young SG
Biochim Biophys Acta; 2008; 1781(1-2):36-9. PubMed ID: 18082640
[TBL] [Abstract][Full Text] [Related]
19. Progeria, the nucleolus and farnesyltransferase inhibitors.
Mehta IS; Bridger JM; Kill IR
Biochem Soc Trans; 2010 Feb; 38(Pt 1):287-91. PubMed ID: 20074076
[TBL] [Abstract][Full Text] [Related]
20. Survey of plasma proteins in children with progeria pre-therapy and on-therapy with lonafarnib.
Gordon LB; Campbell SE; Massaro JM; D'Agostino RB; Kleinman ME; Kieran MW; Moses MA
Pediatr Res; 2018 May; 83(5):982-992. PubMed ID: 29342131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
